Skip to content

Companies

Product Development

The product development segment consists of biotech and pharma companies advancing products or technologies to proof-of-concept, clinical or otherwise, and towards marketing approval. These companies have a massive valuation uplift potential and a clear pathway to success. Flerie encourages partnering, licensing and expansion of the investor base to provide resources or opportunities. Flerie remains engaged to the appropriate endpoint, which could include the company entering commercial growth.
flerie-alder-logo
flerie-alder-logo-overlay

Alder Therapeutics

Alder Therapeutics, founded in 2021 by Kristian Tryggvason, is a newly formed Swedish pre-clinical stage biotech, based on discoveries and IP generated by and licensed from DUKE-NUS Medical School in Singapore and Biolamina (which Kristian co-founded). Alder focuses on building a novel cell therapy platform with the best functional cells based on the most simple and robust processes. Alder is a virtual company working with leading cell therapy experts around the world, and have established a strategic partnership with NorthX Biologics. Their unique platform, initially focusing on retinal and cardiac cell therapeutic products, will allow for better pluripotent cell therapy treatment for the wider masses.
Sweden
Kristian Tryggvason
flerie-amarna-logo
flerie-amarna-logo-overlay

Amarna Therapeutics

Amarna is a preclinical stage biotech company based in Leiden, the Netherlands, developing a non-immunogenic viral vector platform (“Nimvec™”) to produce new gene replacement therapies and new auto-antigen based tolerance induction therapies. All other gene therapies currently in development or already approved typically induce a strong immune response, resulting in that these therapies can only be dosed once, and that in many patients there is a lack of efficacy. Nimvec™ is unique in that it does not induce an immune response. Instead, administration of Nimvec™ moderates the immune system to induce tolerance for any genes that are included in the Nimvec™ vector. Thus, the advantages of Nimvec™ are twofold:  
  1. Gene Replacement Therapy (GRT) with Nimvec™ allows for multiple dosing (instead of only once), to ensure consistent and sustainable treatment of patients with genetic disorders.
  2. Induction of Tolerance Therapy (ITT) for autoimmune diseases with known auto antigens.
Netherlands
Henk Streefkerk
flerie-anacardio-logo
flerie-anacardio-logo-overlay

AnaCardio

AnaCardio is a Swedish clinical stage biopharmaceutical company developing novel drugs to treat heart failure, increasing contractility with a unique and proprietary mechanism of action. It is based on Professor Lars Lund’s research at Karolinska Institutet on the ghrelin peptide, demonstrating an improvement of heart function in a proof-of-concept trial in patients without increasing oxygen consumption, arrhythmia, ischaemia, or hypotension. The lead program AC01 is an in-licensed oral peptidomimetic small-molecule being investigated in a phase Ib/IIa clinical study in 2023 in patients with heart failure and reduced ejection fraction. If proven successful, AC01 can be recognised as having block-buster potential in an area with a high unmet need.
Sweden
Patrik Strömberg
flerie-atrogi-logo
flerie-atrogi-logo-overlay

Atrogi

Atrogi is a company in clinical phase developing a first-in-class drug for the oral treatment of type 2 diabetes, based on Professor Tore Bengtsson’s research at Stockholm University. The lead compound, ATR-258, is a new small molecular compound, targeting the β2-adrenoreceptor (β2-AR) in a novel way, leading to stimulation of glucose uptake in skeletal muscle, independently of the insulin signaling pathway. This leads to improvement in glycaemic control with several additional advantageous non-glycaemic effects. A phase 1 trial is ongoing with the lead candidate ATR-258 in healthy volunteers and patients for patients with type 2 diabetes. There is large interest from big pharma for a drug with such an effective and competitive profile, with blockbuster potential.
Sweden
Alexandra Ekman Ryding
flerie-buzzard-logo
flerie-buzzard-logo-overlay

Buzzard Pharma

Buzzard Pharma is a Swedish clinical stage oncology company developing a potent Interleukin-1 inhibitor, Isunakinra, for the treatment of solid tumors in combination with a PD-1 inhibitor (checkpoint inhibitor). Isunakinra is a chimeric protein binding to IL1R1, inhibiting signaling with high potency. The rights to the drug were acquired from Eleven Biotherapeutics in 2017, repositioning the drug from the ophthalmology area to oncology. Isunakinra is currently in phase I/II in solid tumour patients at the Baylor Research Institute in Dallas, Texas. The company was founded by serial biotech entrepreneur Maarten de Château, founder of Cormorant Pharmaceuticals, sold to Bristol Myers Squibb in 2016 for up to $520 million.
Sweden
Maarten de Château

Egetis Therapeutics

Egetis Therapeutics is a publicly listed Swedish company, formed by the merger of PledPharma and Rare Thyroid Therapeutics in 2020. It is a dedicated orphan drug development company with two late-stage orphan drug assets: Emcitate® for treatment of MCT8 deficiency and and Aladote® for prevention of acute liver injury caused by paracetamol poisoning. Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in 2023 based on existing clinical data and a new drug application (NDA) in the US in 2024 following the read-out of the registrational ReTRIAC trial.
Sweden
Nicklas Westerholm

Empros

Empros Pharma is a clinical stage company developing EMP16, an oral weight-loss medication. The product is a re-purposing of established weight-loss and diabetes drugs (orlistat and acarbose). The new controlled-release formulation has an impressive therapeutic effect, while avoiding the troublesome side effects of the two compounds on their own, improving compliance and quality of life. Their aim is to develop a safe oral first-line treatment for this growing patient group, with additional opportunities for paediatric, OTC and maintenance use. In 2024 Empros reported positive topline data for a phase 2b trial that met its primary endpoint demonstrating significantly greater weight loss than orlistat alone. The company is preparing to enter phase III trials.
Sweden
Arvid Söderhäll
flerie-epiendo-logo
flerie-epiendo-logo-overlay

EpiEndo

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity to reduce disease-causing inflammation. Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin. A breakdown of this barrier is implicated in several chronic inflammatory diseases. EpiEndo’s new class of orally available macrolide, with reduced AMR effect, known as a ‘Barriolide’, shows promise as a first-in-class therapeutic for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, is the first Barriolide to enter into Phase II clinical trials, for chronic obstructive pulmonary disease (COPD). EP395, aims to be the first on-market oral, barrier strengthening and anti-inflammatory macrolide with reduced AMR effect, for the treatment of COPD, which has a significant unmet need. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD projected to cost $4.8 trillion by 2030.
Iceland
Maria Bech
flerie-geneos-logo
flerie-geneos-logo-overlay

Geneos Therapeutics

Geneos Therapeutics, a US-based clinical stage biotherapeutics company believes that the company’s personalized therapeutic cancer vaccines (PTCVs) may serve an important role in new immunotherapeutic paradigms for cancer. The company’s approach, using its proprietary GT-EPIC™ platform, is to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and uniquely personalized treatments for cancer. They are targeting solid tumours, initially liver cancer (hepatocellular carcinoma, HCC). There is an ongoing phase Ib/IIa trial in second-line HCC patients, with initial encouraging results, including a number of complete responses pointing towards a potential cure in a patient group known for its poor prognosis. The company is planning a potentially registrational clinical trial and has established manufacturing supply partnerships, notably an in-depth collaboration with sister company NorthX Biologics. As manufacturing turnaround time is of utmost importance for these cancer patients, NorthX has geared up to support Geneos by optimising for a fast turnaround of these GMP plasmid DNA vaccines to significantly less than the industry standard of 12 weeks.
US
Niranjan Sardesai
flerie-kahr-logo
flerie-kahr-logo-overlay

KAHR

KAHR is an Israeli clinical stage cancer immunotherapy company developing novel bi-functional fusion proteins. Their customizable immuno-recruitment cancer drug candidates utilise various methods to synergistically disable cancer defenses and activate a targeted response involving both innate and adaptive immunity. Their Multifunctional Immune Recruitment Protein (MIRP) platform is used to develop next generation solid and haematological tumour treatments with a number of ongoing clinical and preclinical programmes. KAHR’s lead product, DSP107, is a first-in-class CD47x41BB targeting agent currently in clinical development for patients with solid tumors.
Israel
Yaron Pereg
flerie-lipum-logo
flerie-lipum-logo-overlay

Lipum

Lipum is a publicly listed Swedish clinical stage drug development company. Its biological anti-inflammatory drug candidate SOL-116 has a novel mechanism of action targeting the BSSL protein (originally found in breast milk). Their initial focus is on the treatment of rheumatoid arthritis, but they are in parallel exploring additional inflammatory diseases with a high unmet medical need such as juvenile idiopathic arthritis and inflammatory bowel disease. Lipum is evaluating SOL-116 in a clinical phase I study in healthy volunteers and patients with rheumatoid arthritis.
Sweden
Ola Sandborgh

Mendus

Mendus is dedicated to changing the course of cancer treatment by addressing tumour recurrence and improving survival outcomes for cancer patients, while preserving quality of life. They are leveraging their unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Their lead programme vididencel will be investigated in a Phase II trial in AML patients in combination with Onureg. It is also being investigated in a Phase I trial (ALISON) for ovarian cancer. In addition, ilixadencel is to be studied in a Phase II proof-of-concept trial in GIST. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
Sweden
Erik Manting
flerie-microbiotica-logo
flerie-micribiotica-log

Microbiotica

Microbiotica is a UK based microbiome company, spun-out from the Sanger Institute in Cambridge, UK in 2016. They are a leading player in the field of microbiome-based therapeutics and biomarkers. The company can identify gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics (LBPs) and biomarkers from clinical datasets, initially focussing on immune-oncology (IO) and ulcerative colitis (UC). Their aim is to develop LBPs that can increase the response rate of cancer patients to immune checkpoint inhibitors and induce remission in patients with inflammatory bowel disease. Microbiotica's two lead products, both orally-delivered capsules containing fully manufactured bacterial consortia, MB097 (immuno-oncology candidate) and MB310 (ulcerative colitis candidate) will be evaluated in Phase 1b clinical studies. In addition to its lead programs, Microbiotica is developing a pipeline of follow-on candidates and biomarkers. Microbiotica has partnered with leading organisations, such as Cancer Research UK, Cambridge University Hospitals, University of Adelaide and Genentech.
UK
Tim Sharpington
flerie-prokranium-logo-b
flerie-prokranium-logo-overlay-b

Prokarium

Prokarium is a UK-based clinical stage biopharmaceutical company, pioneering the field of microbial immunotherapy. Their pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. It builds on the natural ability of their bacterial strains to seek out and colonise solid tumours. They have developed attenuated strains capable of targeting tumours without causing pathology in normal tissues. These strains are also capable of delivering specific immunostimulatory cargo aimed at activating the patient’s immune system to destroy tumours. In parallel, the company is developing an oral RNA platform.
UK
Kristen Albright
flerie-sixeria-logo
flerie-sixeria-logo-overlay

Sixera Pharma

Sixera Pharma is a Swedish clinical stage company developing a new treatment for Netherton syndrome, an ultra-orphan (very rare) and serious skin condition. The lead candidate SXR1096 is a small molecule formulated in a cream that is applied topically on the skin, comprising of a specific inhibitor of certain proteases (Kallikreins 5, 7, and 14). SXR1096 has the potential of becoming the first available treatment for this patient group, and it has received orphan drug designation (ODD) both by the EMA and the FDA for the treatment of Netherton syndrome. A phase I/II proof of concept study is being carried out to evaluate the safety and efficacy of the drug in patients at five European sites. The company’s CEO is serial biotech entrepreneur Maarten de Château, founder of Cormorant Pharmaceuticals, sold to Bristol Myers Squibb in 2016 for up to $520 million.
Sweden
Maarten de Château
flerie-strike-logo
flerie-strike-logo-overlay

Strike Pharma

Strike Pharma is a Swedish company founded by KOL and serial entrepreneur Sara Mangsbo in 2021, developing a novel next generation Antibody-Drug Conjugate (ADC) technology within the immuno-oncology precision medicine space, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve the delivery of tailor-made synthetic molecules to specific cell types for improved immune modulation. Their aim is to take precision medicine to a new level, enabling development of individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatments offer the potential to increase therapeutic efficacy and reduce dosage levels thereby minimizing the risk of side effects. Their lead molecule STRIKE2001-KRAS, covering multiple KRAS mutations, is currently in preparation for phase I trials.
Sweden
Mårten Winge
flerie-synerkine-logo
flerie-synekine-logo-overlay

Synerkine Pharma

Synerkine Pharma is a Dutch biopharmaceutical company developing a novel class of biologics, called Synerkines, that connect two different anti-inflammatory cytokines and enhance their activity via a unique mode of action. Their initial focus is on chronic pain. The company’s lead programme SK-01 is a fusion of interleukins IL-4 and IL-10 for complex regional pain syndrome, a severe form of chronic pain, and osteoarthritis. The SK-02 programme is a fusion of IL-4 and IL-13 and is being developed for in chemotherapy-induced peripheral neuropathy (CIPN). Synerkine Pharma has proof of concept data in relevant animal models for the first in human indication and is working on the next development steps towards a first clinical trial. The ability to treat chronic pain with drugs that mimic endogenous immune molecules and are based on a different mechanism of action than the traditional analgesic drugs holds tremendous therapeutic and commercial potential.
Netherlands
Hans Preusting
flerie-toleranzia-logo
flerie-toleranzia-logo-overlay

Toleranzia

Toleranzia is a publicly listed Swedish drug development company aiming to restore the immune system’s normal ability to tolerate the endogenous substances that are mistakenly targeted in patients suffering from severe autoimmune diseases. The Company’s tolerogens have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune disease for which they are developed. Toleranzia's primary drug candidate, TOL2, is being developed as a treatment for the autoimmune orphan disease myasthenia gravis, which is a chronic and progressive disease that causes gradually increasing muscle weakness. The second drug candidate, TOL3, is being developed as a treatment for the autoimmune orphan disease ANCA vasculitis, which is a chronic and progressive disease that causes blood vessel inflammation and damage to blood vessel walls. The company is currently in the process of scaling up the production of TOL2 in collaboration with their manufacturing partner in preparation for their upcoming phase I/IIa clinical trial in myasthenia gravis patients.
Sweden
Charlotte Fribert
flerie-vitara-logo
flerie-vitara-logo-overlay

Vitara Biomedical

Vitara Biomedical is a US-based MedTech company in the preclinical phase of development. Inspired by nature, Vitara is developing a fluid-filled incubator for premature infants to reduce mortality and improve quality of life compared to the current standard of care. By reducing lifelong complications such as bronchial pulmonary dysplasia, chronic lung disease, sepsis, loss of vision, and necrotizing enterocolitis the quality of life of the baby could be dramatically improved.
US
James McGlone
flerie-xintela-logo
flerie-xintela-logo-overlay

Xintela

Xintela is a publicly listed Swedish biopharma company developing allogeneic stem cell-based treatments focusing on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancer. Xintela's programmes are based on a unique cell marker technology platform, utilising the cell surface molecule integrin α10β1. The lead programme, investigating the stem cell product XSTEM in knee osteoarthritis, started a clinical phase I/IIa study in Australia in April 2022. The second programme, in difficult-to-heal venous leg ulcers was initiated in September 2022, with a clinical phase I/IIa study in Sweden. XSTEM is manufactured in Xintela’s own GMP facility. Targinta is in preclinical stage with two antibody leads candidates; the antibody-drug conjugate (ADC) TARG9 and the function/blocking antibody TARG10, targeting integrin α10β1 in triple-negative breast cancer and the brain cancer glioblastoma. The next step is to validate the target and treatment concept in an innovative 'Clinical phase 0 study' in cancer patients.
Sweden
Evy Lundgren

XNK Therapeutics

XNK Therapeutics is a Swedish clinical stage immunotherapy company focusing its efforts on preventing and treating cancer by developing unique and individualised NK cell-based therapies. Their autologous lead drug candidate, evencaleucel, is being investigated in a phase II study in combination with Sanofi’s anti CD 38 monoclonal antibody Sarclisa (isatuximab) as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients. There is also ongoing research and development targeting both haematologic malignancies and solid tumours (initially bladder cancer) in mono- and combination therapy. The company has collaborations with Sanofi and MD Andersson Cancer Center. XNK has developed a proprietary technology platform of broad utility and benefits from its tailormade GMP facility, in addition to its attractive co-location with the Karolinska Institutet and the Karolinska University Hospital.
Sweden
Johan Liwing

Xspray Pharma

Xspray Pharma is a Swedish publicly listed pharmaceutical company developing improved protein kinase inhibitors (PKIs) for the treatment of cancer using an innovative technology platform. PKIs are the second largest group of drugs in oncology, whereby drug prices are high. Xspray use their innovative, patented RightSize™ technology to develop improved stable amorphous versions of marketed drugs. This allows them to gain entry as the first competitor to today’s original drugs before the secondary patents expire. The current pipeline includes improved versions of three blockbuster cancer drugs Sprycel®, Tasigna® and Inlyta® plus an undisclosed pipeline. Their lead candidate Dasynoc (XS004) has achieved bioequivalence with a 30 percent lower dose compared to the original drug, Sprycel®, and is unaffected by the pH value of the stomach. Therefore this improved version can thus be used together with omeprazole without affecting the absorption of dasatinib, which facilitates treatment of peptic ulcers while the patient is being treated for cancer. There is an ongoing litigation process with Bristol Myers Squibb relating to the IND submission of Dasynoc with the FDA, which was completely expected by the company.
Sweden
Per Andersson